Summarized by Masters of Longevity from Lifespan.io.
FDA signaled regulatory focus on longevity while Life Biosciences reported early human OSK gene therapy results.
Key Takeaways
- FDA is engaging regulatory science for aging biology.
- Life Biosciences has reported interim Phase 1 OSK results.
- Findings are early and causal benefit remains unproven.
